In previous studies, METTL3 was found to have an adverse influence on acute myeloblastic leukaemia (AML), breast cancer (BC), ovarian carcinoma, bladder cancer (BC) and gastric cancer (GC) [17–22]. Here, METTL3 is linked to acute myeloid leukemia.